{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-158461","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.184755+00:00","generated_at":"2026-06-01T05:03:36.559415+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan","bullets":["Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.","2024 Equity Incentive Plan approved: 53.96M for, 17.0M against, 24.84M broker non-votes.","Automatic annual increase to 2024 Equity Incentive Plan rejected: 26.63M for, 44.29M against.","Ratified Deloitte & Touche as auditors for FY2024: 89.69M for, 6.08M against.","Two directors elected: William K. Heiden and Ameet Mallik, each with >64M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-158461","json":"https://secwatch.observer/filing/0001193125-24-158461.json","markdown":"https://secwatch.observer/filing/0001193125-24-158461.md","text":"https://secwatch.observer/filing/0001193125-24-158461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/0001193125-24-158461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/d741804d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:03:36.559415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}